Sofosbuvir 
 
Sofosbuvir  400 mg and Velpatasvir  100 mg tablets
Ingredients : Each film-coated tablet contains 400 mg of Sophibuvir and 100 mg of Wilpatasvir.
Indications : Suitable for the treatment of adult patients with chronic hepatitis C virus infection of type 1 , 2 , 3 , 4 , 5 or 6 , without cirrhosis or compensated cirrhosis, decompensated cirrhosis can be combined with ribavirin Used in combination.
Dosage and administration : The recommended dose of sofosbuvir and verapamil is an oral tablet, once a day, before and after meals. The recommended treatment plan and duration based on the patient population are as follows :
Patient criteria
Treatment plan and duration
Patients without cirrhosis and patients with compensated cirrhosis
Sofosbuvir INN 400mg & Velpatasvir 100mg 12 weeks
Patients with decompensated cirrhosis (hepatitis B or C)
Sofosbuvir INN 400mg & Velpatasvir 100mg + ribavarin 12 weeks
Or follow the instructions of a registered doctor.
Side effects : The most common side effects are fatigue, anemia, nausea, headache, insomnia and diarrhea. The potential risk of HVB virus reactivation in patients co-infected with HBV virus and hepatitis C virus , the interaction with vitamin K antagonists, and the change of INR value.
Contraindications : In patients who are contraindicated with ribavirin, ban Sofosbuvir and Velpastavir combined with ribavirin. Precautions : When Sofosbuvir is combined with amiodarone and another hepatitis C virus direct antiviral drug When combined, severe symptomatic bradycardia may occur. It is not recommended to combine amiodarone with sofosbuvir/velpatasvir . Drug interactions : Sofosbuvir & Velpatasvir may interact with the following drugs : omeprazole, topotecan, carbamazepine, phenytoin, phenobarbital, rifapentin, St. John's wort.
Overdose : There is no specific antidote for overdose of sofebuvir / verapamil. If an overdose occurs, the patient must be monitored for toxicity. For pregnancy and breastfeeding : There are no adequate and well-controlled studies on pregnant women. This drug should only be used when the potential benefits outweigh the potential risks to the fetus. It is not yet known whether sofosbuvir & velpatasvir or its metabolites will be excreted in breast milk. It is recommended that women receiving sofosbuvir & velpatasvir do not breastfeed.
Storage : Store in a cool and dry place below 30 ℃ . Protect from light and moisture. Keep the medicine out of the children's reach.